
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
Lucian Ionescu joined UCB in 2006, and since then, has contributed to building the immunology franchise through a track record of strategic and operational leadership roles, in Global Brand Leadership (Cimzia Pre/Launch and Commercial Implementation), Strategic Projects and Early Medicines (Bimzelx Early Development), Medical and Clinical Affairs, Global Corporate, in Europe and the United States. He built twice medical affairs organizations (Global and US), and acted as a global project leader for two launches, in rheumatology Cimzia NR axSpA and dermatology Cimzia PsO. Lucian combines passion for science with translation into patient value. He is versatile in understanding the commercial processes, marketplace dynamics, stakeholders, ecosystems, towards integration and decision-making for value creation holistically.
Lucian is a Medical Doctor (MD), and before joining UCB, has worked as a clinician in Romania, and as a scientist at University of Pennsylvania. Over his 22 yrs of professional career, he published in multiple scientific journals; he holds an MBA from Vlerick Business School, a top-100-business school, and executive degrees from Wharton, MIT, Insead and IMD (Executive Management, Artificial Intelligence and Business Strategy).
Since Sep 2019, Lucian leads the European Immunology Commercial Operations at UCB, and is responsible for evolving the business from one biologic/one therapeutic area to a portfolio of biologics across three therapeutic areas (rheumatology, dermatology, osteoporosis). Passionate about Digital Business Transformation, he and the team aspire to partner internally and externally towards contributing to digitizing and optimizing the health care system, while benefiting patients of innovative medicines across Europe during the next few years.
Achieving ACR50 is associated with improvements in quality of life for patients with PsA.1 Dive into the data supporting higher treatment targets in clinical...
Watch Prof Lars Erik Kristensen and Prof Frank Behrens discuss how MDA is a realistic treatment target in clinical practice and the barriers to achieving it for...
Treatment for PsA should target a broad range of musculoskeletal and extra-articular manifestations.1 Listen to Assoc. Prof Philipp Sewerin explain how MDA can...
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
axSpA is a complex disease with a significant burden on many aspects of daily life.1,2 Dive into the importance of ASAS40 for your patients with Dr Fabian Proft.
Watch Prof Robert Landewé discuss the importance of using ASDAS <2.1 as a treatment target for patients with axSpA.